Saturday, July 11, 2026

Drug profile · INN

somapacitan

somapacitan (SOGROYA) is a growth hormone receptor agonist.

EMA: approved NMPA: clinical trials Systemic hormonal preparations (H01) H01AC07
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — somapacitan
Class
Systemic hormonal preparations (H01)
Route
Patents
0
Programs
5
Data quality
0.83

Quick answer

somapacitan (SOGROYA) is a growth hormone receptor agonist.

Key facts

INN somapacitan
Brand SOGROYA
Mechanism Growth hormone receptor agonist
Target Growth hormone receptor
Therapeutic class Systemic hormonal preparations (H01)
ATC code H01AC07

Mechanism of action

Growth hormone receptor agonist

Primary target: Growth hormone receptor

Approval history

Authority Status Date
EMA approved
NMPA clinical trials

Pipeline programs

  1. NN8640-4263 Phase 3 · NovoThirteen · Growth Hormone Deficiency in children
  2. NN8640-4467 Phase 3 · NovoThirteen · Children with short stature either born small for gestationa
  3. Somapacitan Phase 3 · Novo Nordisk A/S · Growth Hormone Deficiency in Children
  4. somapacitan Phase 3 · Novo Nordisk A/S · Growth Hormone Disorder
  5. NN8640-4245 Phase 2 · NovoThirteen · SGA - small for gestational age children

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is somapacitan?

somapacitan (SOGROYA) is a growth hormone receptor agonist.

What is the brand name for somapacitan?

SOGROYA is a marketed brand name for somapacitan. Check FDA Drugs@FDA for the current US label holder and prescribing information.